<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700930</url>
  </required_header>
  <id_info>
    <org_study_id>2018-01111</org_study_id>
    <nct_id>NCT04700930</nct_id>
  </id_info>
  <brief_title>CBD Cigarettes Instead of Normal Cigarettes as Innovative Treatment for Schizophrenia</brief_title>
  <official_title>CBD Cigarettes Instead of Normal Cigarettes Against Enforcement Measures, for Improved Acute Treatment and for Harm Reduction of Smoking - Innovative Treatment for Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psychiatric Hospital of the University of Basel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Psychiatric Hospital of the University of Basel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Interventional study using Cannabidiol containing cigarettes as replacement of usual&#xD;
      cigarettes&#xD;
&#xD;
      Reduction of enforcement measures, improved acute treatment, harm reduction, and improvement&#xD;
      of psychotic symptoms&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 4, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in psychotic symptoms</measure>
    <time_frame>1 Months (acute therapy), 6 Months (Follow up)</time_frame>
    <description>To measure changes in psychotic symptoms weekly PANNS (Positive and Negative Syndrome Scales) are used. This is a validated medical scale used for measuring symptom severity of patients with schizophrenia. The patient is rated from 1 to 7 on 30 different symptoms based on a clinical interview. Minimum Score = 30, Maximum Score = 210 Points. Lower Scores mean less positive / less negative / less general psychopathological symptoms, which is better. Higher scores mean more postive / negativ / general psychopathological symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in violent behaviour.</measure>
    <time_frame>1 Month (acute therapy), 6 Months (Follow up)</time_frame>
    <description>Violent behaviour will be assessed through clinical staff via the The Brøset Violence Checklist. It is a clinical evaluation indicating the presence or absence of violent behaviour. The scale consists of 6 items. Minimum score = 0, Maximum score = 6. The lower the score, the better. A low score indicates a lower potential of violent behaviour and lower actual violent behaviour.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in depressive Symptoms</measure>
    <time_frame>1 Month (acute therapy), 6 Months (Follow up)</time_frame>
    <description>To measure changes in depressive Symptoms weekly BDI-II (Becks Depression Inventory) will be conducted (minimum = 0 points, maximum = 63 points). A higher score means more severe depression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in subjective well being under neuroleptic medication</measure>
    <time_frame>1 Month (acute therapy), 6 Months (Follow up)</time_frame>
    <description>Subjective Well-Being under Neuroleptics Scale short form (SWN-K) will be used to assess individual well-being on a weekly basis. (Minimum = 20, Maximum = 120 points). Higher scores mean higher subjective well-being.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of necessary neuroleptic medication</measure>
    <time_frame>1 Month (acute therapy), 6 Months (Follow up)</time_frame>
    <description>We will register the patients neuroleptic medication. For the conversion of the participants' antipsychotic medication the Defined Daily Dose method by Leucht et al. (2016) was applied. Each participants' antipsychotic medication was converted to olanzapine equivalents in mg per day using the antipsychotic dose conversion calculator provided by Leucht and colleagues (Leucht et al., 2020).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of Isolation-Events (enforcement measures)</measure>
    <time_frame>1 Month (acute therapy), 6 Months (Follow up)</time_frame>
    <description>The total number of necessary Isolations of participants in CBD-arm and non-CBD-arm will be compared. The total number of actual isolation events will be compared</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of enforced medication-events (enforcement measures)</measure>
    <time_frame>1 Month (acute therapy), 6 Months (Follow up)</time_frame>
    <description>The number of necessary events of enforced medication of participants in CBD-arm and non-CBD-arm will be compared. The total number of actual enforced medication-events will be compared.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tobacco use</measure>
    <time_frame>1 Month (acute therapy), 6 Months (Follow up)</time_frame>
    <description>Number of normal tobacco cigarettes and CBD-Cigarettes will be measured by a daily self-reporting-scale of the participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cannabis use</measure>
    <time_frame>1 Month (acute therapy), 6 Months (Follow up)</time_frame>
    <description>Number of cannabis-joints will be measured by weekly self-reports of the participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of CBD and THC levels with psychotic symptoms via PANSS</measure>
    <time_frame>1 Month (acute therapy), 6 Months (Follow up)</time_frame>
    <description>The study aims to correlate CBD and THC whole blood levels with psychotic symptoms via PANSS scores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Schizophrenia and Other Psychotic Disorders</condition>
  <condition>Harm Reduction</condition>
  <arm_group>
    <arm_group_label>CBD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive CBD cigarettes additionally to standard psychiatric care including neuroleptic medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-CBD</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients recieve standard psychiatric care including neuroleptic medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CBD-Cigarettes</intervention_name>
    <description>CBD-Cigarettes instead of normal Cigarettes: The participants in this arm receive CBD-Cigarettes which are then inhaled/smoked instead of their normal tobacco cigarettes</description>
    <arm_group_label>CBD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Schizophrenia or Related Disorders&#xD;
&#xD;
          -  PANNS &gt; 21,&#xD;
&#xD;
          -  Tobacco-smokers&#xD;
&#xD;
          -  inpatient status&#xD;
&#xD;
          -  within age 18 - 65 years&#xD;
&#xD;
          -  German-speaking&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  personality disorder&#xD;
&#xD;
          -  non-smokers&#xD;
&#xD;
          -  organic psychotic diseases&#xD;
&#xD;
          -  breast feeding&#xD;
&#xD;
          -  pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Undine Lang, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitäre Psychiatrische Kliniken</name>
      <address>
        <city>Basel</city>
        <zip>4002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>June 17, 2021</last_update_submitted>
  <last_update_submitted_qc>June 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Psychiatric Hospital of the University of Basel</investigator_affiliation>
    <investigator_full_name>Prof. Stefan Borgwardt</investigator_full_name>
    <investigator_title>Principle Investigator, Clinical Professor, Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

